Nasdaq
$20.58▼ 2.05%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $958.5MShares out 46.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 6d agoPre-market26.10.19 21:088-KKey event#●●●#●●●#●●●
ArriVent BioPharma, Inc.Bullish
ArriVent BioPharma announced the publication of Phase 1b (FURMO-002) results for firmonertinib in Cancer Cell, demonstrating significant clinical activity in EGFR PACC-mutant NSCLC patients. The study reported confirmed overall response rates of 43% at 160 mg and 68% at 240 mg, supporting the company's ongoing global Phase 3 ALPACCA trial. This data reinforces the potential of firmonertinib as a first-in-class targeted therapy for this underserved patient population.…more
$20.58-2.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13After-hours26.10.14 05:01SCHEDULE 13GOwnership
ArriVent BioPharma, Inc.
Six entities, including Vivo Opportunity Fund Holdings, L.P., have filed a Schedule 13G to report their collective ownership stake in ArriVent BioPharma, Inc. The investors have agreed to jointly file any subsequent amendments regarding their holdings.…more
$20.58-2.05%vs prev closeView filingShare - 10.13Pre-market26.10.13 19:038-KKey event
ArriVent BioPharma, Inc.
ArriVent BioPharma has successfully dosed the first patient in its U.S. Phase 1 clinical trial for ARR-002, a novel MUC16/NaPi2b dual-target tetravalent antibody-drug conjugate (ADC) targeting ovarian and endometrial cancer. This milestone marks the expansion of the company's clinical pipeline beyond its existing programs in lung and gastrointestinal cancers.…more
$20.58-2.05%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 59m agoClosed26.10.25 22:00Bullish#●●●#●●●#●●●
ArriVent Reports Encouraging Phase 1 Data for CDH17-targeted ADC ARR-217…more
ArriVent announced positive initial Phase 1 results for its CDH17-targeting ADC, ARR-217, demonstrating significant anti-tumor activity in gastrointestinal cancer patients. The company plans to advance the candidate into a Phase 1b dose optimization study based on these findings.…more
$20.58-2.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 1d agoAfter-hours26.10.24 05:00
●●●●●●●● ●●●●● ●●●●●●
ArriVent will present initial safety and efficacy data from the Phase 1 study of its CDH17-targeted ADC, ARR-217, in patients with gastrointestinal cancers at the ESMO Congress 2026. The company plans to host a virtual webinar to discuss the clinical findings following the presentation.…more
$20.58-2.05%vs prev close - 6d agoPre-market26.10.19 21:01
●●●●●●●● ●●●●● ●●●●●●
ArriVent BioPharma announced the publication of Phase 1b clinical results for its lung cancer candidate, firmonertinib, in the journal Cancer Cell. While the data highlights potential efficacy in EGFR PACC-mutant NSCLC, the company is currently advancing toward Phase 3 trials, making the impact of this publication neutral.…more
$20.58-2.05%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report